Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?

Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?

The median survival time has been reported to vary between 5 and 8 years in low-grade (WHO grade 2) astrocytoma, and between 10 and 15 years for grade 2 oligodendroglioma. Targeted alpha therapy (TAT), using the modified peptide vector [<sup>213</sup>Bi]Bi/[<sup>225</sup>Ac]A...

Full description

Bibliographic Details
Main Authors: Leszek Krolicki, Jolanta Kunikowska, Dominik Cordier, Nedelina Slavova, Henryk Koziara, Frank Bruchertseifer, Helmut R. Maecke, Alfred Morgenstern, Adrian Merlo
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:International Journal of Molecular Sciences
Subjects:
TAT (targeted alpha therapy)
Bismuth-213
Actinium-213
brain tumors
low-grade glioma
astrocytoma
Online Access:https://www.mdpi.com/1422-0067/24/21/15701

Internet

https://www.mdpi.com/1422-0067/24/21/15701

Similar Items